Search

Your search keyword '"Malpica A"' showing total 234 results
Start Over Author "Malpica A" Journal blood
234 results on '"Malpica A"'

2. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma

Author

Ranjit Nair, Rishab Prakash, Anna Dang, Jillian R. Gunther, Auris Huen, Jie Xu, Luis Enrique Malpica Castillo, Carlos Torres Cabala, Meghan Heberton, Penny Fang, Sairah Ahmed, Roberto N. Miranda, Luis Fayad, Raphael Steiner, Hun Ju Lee, Dai Chihara, Preetesh Jain, Samer A Srour, Jeremy L Ramdial, Yago Nieto, Loretta J. Nastoupil, Chelsea C. Pinnix, Sattva S. Neelapu, Christopher R. Flowers, L. Jeffrey Medeiros, Chitra Hosing, Michael L. Wang, Bouthaina S. Dabaja, Francisco Vega, Lei Feng, and Swaminathan Padmanabhan Iyer

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

3. Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Luis Mario Villela Martinez, Brady E. Beltrán, Marialejandra Alejandra Torres Viera, Henry Idrobo, Myrna Candelaria, Guilherme Fleury Perini, Ana Carolina Oliver, Denisse Castro, Rosa Oliday, Sally Rose Paredes, Ana Florencia Ramirez-Ibarguen, Lidiane Andino, Silvia Rivas-Vera, Seisha Alana Von Glasenapp Gossen, Victoria Irigoin, Gladys P Agreda, Fernando Perez-Jacobo, Perla R.R. Colunga-Pedraza, Efreen Montaño Figueroa, Lorena Fiad, Fabiola Valvert, Camila Peña, Jose A Hernández-Hernández, Virginia Otero, Melani Otañez, Guillermo J. Ruiz-Arguelles, Arianna Robles, Carlos Best, David Gomez-Almaguer, Rosio Baena, Saul Urquijo, Eleazar Hernandez, Jose Luis Álvarez, Melissa Castro, Jorge J. Castillo, and Luis Enrique Malpica Castillo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

4. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Author

Andrew Jallouk, Lei Feng, Mansoor Noorani, Kaberi Das, Raphael E Steiner, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Jason Westin, Luis Fayad, Dai Chihara, Luis Enrique Malpica Castillo, Swaminathan P. Iyer, Sairah Ahmed, Elizabeth J Shpall, Partow Kebriaei, Sattva S. Neelapu, and Paolo Strati

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

5. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Author

Preetesh Jain, Chi Young Ok, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Fatima Zahra Jelloul, Holly Hill, Kristen Floyd, Sanam Loghavi, Zhuang Zuo, C. Cameron Yin, Mark Routbort, Guilin Tang, Sairah Ahmed, Luis Enrique Malpica Castillo, Asiya Siddiqui, Wendy Chen, Onyeka Oriabure, Maria Badillo, Raphael E Steiner, Swaminathan P. Iyer, Hun Ju Lee, Rajyalakshmi Luthra, Francisco Vega, Christopher R. Flowers, Jeffrey Medeiros, Michael L. Wang, Keyur P. Patel, Nathan H. Fowler, and Ranjit Nair

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

6. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Ranjit Nair, Amy Ayers, Loretta J. Nastoupil, Jillian R. Gunther, Luis Fayad, Nathan H. Fowler, Roberto N. Miranda, Fredrick B. Hagemeister, Hun Ju Lee, Maria Alma Rodriguez, Raphael Steiner, Paolo Strati, Yago Nieto, Jeremy L. Ramdial, Dai Chihara, Michael L. Wang, Luis E Malpica Castillo, Neeraj Saini, Preetesh Jain, Chelsea C. Pinnix, Bouthaina S. Dabaja, Michael R Green, Christopher R. Flowers, L. Jeffrey Medeiros, Mario L. Marques-Piubelli, Francisco Vega, Mansoor Noorani, Sairah Ahmed, Jason Westin, Sattva S. Neelapu, Lei Feng, and Swaminathan Padmanabhan Iyer

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

7. Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Ana Carolina Oliver, Luis Mario Villela Martinez, María Victoria Irigoín, María Lorena Cardozo, Seisha Alana Von Glasenapp Gossen, Macarena Alejandra Roa Salinas, Marialejandra Alejandra Torres Viera, Virginia Lema, Denisse Castro, Jose Alvarez, Fernando Perez-Jacobo, Arianna Robles, Melani Otañez, Camila Peña, Virginia Bradvica, Sally Rose Paredes, Guilherme Fleury Perini, Henry Idrobo, Brady E Beltran, Luis Enrique Malpica Castillo, and Jorge J. Castillo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

8. Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Author

Valcarcel, Bryan, primary, Sano, Haruhiko, additional, Katsuya, Hiroo, additional, Utsunomiya, Atae, additional, Otsuka, Maki, additional, Miyahara, Masaharu, additional, Takamatsu, Yasushi, additional, Ishitsuka, Kenji, additional, Kimura, Shinya, additional, Suzumiya, Junji, additional, Tamura, Kazuo, additional, Enriquez, Daniel J, additional, Castro, Denisse, additional, Beltran, Brady E, additional, Idrobo, Henry, additional, Peña, Camila, additional, Fiad, Lorena, additional, Ramos, Juan Carlos, additional, and Malpica Castillo, Luis Enrique, additional

Published
2022
Full Text
View/download PDF

9. Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Author

Hu, Bei, primary, Atrash, Shebli, additional, Cohen, Leah, additional, Barta, Stefan K., additional, Zhang, Yumeng, additional, Sokol, Lubomir, additional, Ayers, Amy, additional, Malpica Castillo, Luis E, additional, Hwang, Steven R, additional, Bennani, N. Nora, additional, Wada, David, additional, Tun, Aung M, additional, Moyo, Tamara K., additional, Ghosh, Nilanjan, additional, and Shinohara, Michi M, additional

Published
2022
Full Text
View/download PDF

10. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, primary, Ayers, Amy, additional, Nastoupil, Loretta J., additional, Gunther, Jillian R., additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Miranda, Roberto N., additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Chihara, Dai, additional, Wang, Michael L., additional, Malpica Castillo, Luis E, additional, Saini, Neeraj, additional, Jain, Preetesh, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Green, Michael R, additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Marques-Piubelli, Mario L., additional, Vega, Francisco, additional, Noorani, Mansoor, additional, Ahmed, Sairah, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

11. Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Author

Valcarcel, Bryan, primary, Sano, Haruhiko, additional, Katsuya, Hiroo, additional, Utsunomiya, Atae, additional, Otsuka, Maki, additional, Miyahara, Masaharu, additional, Takamatsu, Yasushi, additional, Ishitsuka, Kenji, additional, Kimura, Shinya, additional, Suzumiya, Junji, additional, Tamura, Kazuo, additional, Enriquez, Daniel J, additional, Castro, Denisse, additional, Beltran, Brady E, additional, Idrobo, Henry, additional, Peña, Camila, additional, Fiad, Lorena, additional, Ramos, Juan Carlos, additional, and Malpica Castillo, Luis Enrique, additional

Published
2022
Full Text
View/download PDF

12. Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Villela Martinez, Luis Mario, primary, Beltrán, Brady E., additional, Torres Viera, Marialejandra Alejandra, additional, Idrobo, Henry, additional, Candelaria, Myrna, additional, Perini, Guilherme Fleury, additional, Oliver, Ana Carolina, additional, Castro, Denisse, additional, Oliday, Rosa, additional, Paredes, Sally Rose, additional, Ramirez-Ibarguen, Ana Florencia, additional, Andino, Lidiane, additional, Rivas-Vera, Silvia, additional, Gossen, Seisha Alana Von Glasenapp, additional, Irigoin, Victoria, additional, Agreda, Gladys P, additional, Perez-Jacobo, Fernando, additional, Colunga-Pedraza, Perla R.R., additional, Montaño Figueroa, Efreen, additional, Fiad, Lorena, additional, Valvert, Fabiola, additional, Peña, Camila, additional, Hernández-Hernández, Jose A, additional, Otero, Virginia, additional, Otañez, Melani, additional, Ruiz-Arguelles, Guillermo J., additional, Robles, Arianna, additional, Best, Carlos, additional, Gomez-Almaguer, David, additional, Baena, Rosio, additional, Urquijo, Saul, additional, Hernandez, Eleazar, additional, Álvarez, Jose Luis, additional, Castro, Melissa, additional, Castillo, Jorge J., additional, and Malpica Castillo, Luis Enrique, additional

Published
2022
Full Text
View/download PDF

13. Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Candelaria, Myrna, primary, Villela, Luis, additional, Torres Viera, Marialejandra Alejandra, additional, Peña, Camila, additional, Roa, Macarena, additional, Zambrano, Daniela, additional, Colunga-Pedraza, Perla R.R., additional, Robles-Rodriguez, Arianna, additional, Pérez-Jacobo, Fernando, additional, Oliver, Ana Carolina, additional, Irigoín, María Victoria, additional, Baena, Rosio, additional, Idrobo, Henry, additional, Paredes, Sally Rose, additional, Oliday, Rosa, additional, Castro, Denisse, additional, Montaño Figueroa, Efreen, additional, Perini, Guilherme Fleury, additional, Malpica Castillo, Luis Enrique, additional, Beltran, Brady E, additional, and Castillo, Jorge J., additional

Published
2022
Full Text
View/download PDF

14. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Author

Jallouk, Andrew, primary, Feng, Lei, additional, Noorani, Mansoor, additional, Das, Kaberi, additional, Steiner, Raphael E, additional, Nastoupil, Loretta J., additional, Hawkins, Misha, additional, Nair, Ranjit, additional, Westin, Jason, additional, Fayad, Luis, additional, Chihara, Dai, additional, Malpica Castillo, Luis Enrique, additional, Iyer, Swaminathan P., additional, Ahmed, Sairah, additional, Shpall, Elizabeth J, additional, Kebriaei, Partow, additional, Neelapu, Sattva S., additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

15. Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Oliver, Ana Carolina, primary, Villela Martinez, Luis Mario, additional, Irigoín, María Victoria, additional, Cardozo, María Lorena, additional, Gossen, Seisha Alana Von Glasenapp, additional, Salinas, Macarena Alejandra Roa, additional, Torres Viera, Marialejandra Alejandra, additional, Lema, Virginia, additional, Castro, Denisse, additional, Alvarez, Jose, additional, Perez-Jacobo, Fernando, additional, Robles, Arianna, additional, Otañez, Melani, additional, Peña, Camila, additional, Bradvica, Virginia, additional, Paredes, Sally Rose, additional, Perini, Guilherme Fleury, additional, Idrobo, Henry, additional, Beltran, Brady E, additional, Malpica Castillo, Luis Enrique, additional, and Castillo, Jorge J., additional

Published
2022
Full Text
View/download PDF

16. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Author

Nair, Ranjit, primary, Prakash, Rishab, additional, Dang, Anna, additional, Gunther, Jillian R., additional, Huen, Auris, additional, Xu, Jie, additional, Malpica Castillo, Luis Enrique, additional, Torres Cabala, Carlos, additional, Heberton, Meghan, additional, Fang, Penny, additional, Ahmed, Sairah, additional, Miranda, Roberto N., additional, Fayad, Luis, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Srour, Samer A, additional, Ramdial, Jeremy L, additional, Nieto, Yago, additional, Nastoupil, Loretta J., additional, Pinnix, Chelsea C., additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Hosing, Chitra, additional, Wang, Michael L., additional, Dabaja, Bouthaina S., additional, Vega, Francisco, additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

17. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Author

Jain, Preetesh, primary, Ok, Chi Young, additional, Fetooh, Ahmed, additional, Kanagal-Shamanna, Rashmi, additional, Jelloul, Fatima Zahra, additional, Hill, Holly, additional, Floyd, Kristen, additional, Loghavi, Sanam, additional, Zuo, Zhuang, additional, Yin, C. Cameron, additional, Routbort, Mark, additional, Tang, Guilin, additional, Ahmed, Sairah, additional, Malpica Castillo, Luis Enrique, additional, Siddiqui, Asiya, additional, Chen, Wendy, additional, Oriabure, Onyeka, additional, Badillo, Maria, additional, Steiner, Raphael E, additional, Iyer, Swaminathan P., additional, Lee, Hun Ju, additional, Luthra, Rajyalakshmi, additional, Vega, Francisco, additional, Flowers, Christopher R., additional, Medeiros, Jeffrey, additional, Wang, Michael L., additional, Patel, Keyur P., additional, Fowler, Nathan H., additional, and Nair, Ranjit, additional

Published
2022
Full Text
View/download PDF

18. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Author

Elias, Alexandra, primary, Prakash, Rishab, additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Malpica Castillo, Luis Enrique, additional, Dabaja, Bouthaina S., additional, Xu, Jie, additional, Medeiros, Jeffrey, additional, Stewart, John, additional, Wang, Wei, additional, Pinnix, Chelsea C., additional, Hunt, Kelly, additional, Clemens, Mark W, additional, Miranda, Roberto N., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

19. Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response

Author

Nguyen, Christopher N, primary, Prakash, Rishab, additional, Duvic, Madeleine, additional, Heberton, Meghan, additional, Dai, Julia, additional, Nair, Ranjit, additional, Malpica Castillo, Luis Enrique, additional, Torres Cabala, Carlos, additional, Feng, Lei, additional, Iyer, Swaminathan Padmanabhan, additional, and Huen, Auris, additional

Published
2022
Full Text
View/download PDF

20. Cutaneous/ Subcutaneous Involvement - an Immuneprivileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Author

Nair, Ranjit, Prakash, Rishab, Dang, Anna, Gunther, Jillian R., Huen, Auris, Xu, Jie, Malpica Castillo, Luis Enrique, Torres Cabala, Carlos, Heberton, Meghan, Fang, Penny, Ahmed, Sairah, Miranda, Roberto N., Fayad, Luis, Steiner, Raphael, Lee, Hun Ju, Chihara, Dai, Jain, Preetesh, Srour, Samer A, Ramdial, Jeremy L, Nieto, Yago, Nastoupil, Loretta J., Pinnix, Chelsea C., Neelapu, Sattva S., Flowers, Christopher R., Medeiros, L. Jeffrey, Hosing, Chitra, Wang, Michael L., Dabaja, Bouthaina S., Vega, Francisco, Feng, Lei, and Iyer, Swaminathan Padmanabhan

Published
2022
Full Text
View/download PDF

21. Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Author

Bryan Valcarcel, Haruhiko Sano, Hiroo Katsuya, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Yasushi Takamatsu, Kenji Ishitsuka, Shinya Kimura, Junji Suzumiya, Kazuo Tamura, Daniel J Enriquez, Denisse Castro, Brady E Beltran, Henry Idrobo, Camila Peña, Lorena Fiad, Juan Carlos Ramos, and Luis Enrique Malpica Castillo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

23. Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Myrna Candelaria, Luis Villela, Marialejandra Alejandra Torres Viera, Camila Peña, Macarena Roa, Daniela Zambrano, Perla R.R. Colunga-Pedraza, Arianna Robles-Rodriguez, Fernando Pérez-Jacobo, Ana Carolina Oliver, María Victoria Irigoín, Rosio Baena, Henry Idrobo, Sally Rose Paredes, Rosa Oliday, Denisse Castro, Efreen Montaño Figueroa, Guilherme Fleury Perini, Luis Enrique Malpica Castillo, Brady E Beltran, and Jorge J. Castillo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

24. Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Author

Bryan Valcarcel, Haruhiko Sano, Hiroo Katsuya, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Yasushi Takamatsu, Kenji Ishitsuka, Shinya Kimura, Junji Suzumiya, Kazuo Tamura, Daniel J Enriquez, Denisse Castro, Brady E Beltran, Henry Idrobo, Camila Peña, Lorena Fiad, Juan Carlos Ramos, and Luis Enrique Malpica Castillo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

25. Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)

Author

Sally Rose Paredes, Luis Malpica Castillo, Juan Carlos Ramos, Ursula Aviles-Perez, Guilherme Fleury Perini, Kelly Meza, Denisse Castro, Maria Elena Cabrera, Juan L. Maradei, Gustavo Sandival-Ampuero, Henry Idrobo, Victoria Otero, Luis Villela, Fabiola Valvert, Camila Peña, Jose Luis Viñuela, Juan Antonio Choque, Maria Virginia Prates, Laura Aguirre-Martinez, Daniel J Enriquez, Marialejandra Torres Viera, Brady E Beltran, Alana Von Glasenapp, Jorge J. Castillo, Marcos Di Stefano, Milagros Altamirano, Luciana Guanchiale, Cristaldo Nancy, Mirna Churin, Andrea Noboa, Pablo Soto, Eduardo M. Sotomayor, Myrna Candelaria, Lorena Fiad, and Eloisa Riva

Subjects
Pediatrics, medicine.medical_specialty, Latin Americans, business.industry, Immunology, Lymphoproliferative disorders, Cell Biology, Hematology, medicine.disease, Biochemistry, Adult T-cell leukemia/lymphoma, Epidemiology, medicine, business
Abstract

INTRODUCTION: Adult T-cell leukemia/lymphoma (ATLL) is a mature peripheral T-cell neoplasm caused by the Human T-cell Leukemia Virus Type 1 (HTLV-1). HTLV-1 infects up to 10 million people worldwide and is most endemic in Southwestern Japan, the Caribbean basin, South America, and Western Africa. In Latin America (LA), Peru and Brazil have the highest prevalence of HTLV-1-related diseases, however, data on ATLL in other LA countries is scarce. ATLL carries a dismal prognosis and is essentially incurable by conventional drugs. We describe the epidemiology, clinical features, treatment, and disease outcome of ATLL encountered in 11 countries in LA. METHODS: We retrospectively analyzed patients (pts) diagnosed with ATLL between January 1995 and December 2019. ATLL cases were classified according to the Shimoyama criteria into acute (A), lymphomatous (L), chronic (C) and smoldering (S). Treatment approaches used as first-line therapy were: 1) chemotherapy alone; 2) combined chemotherapy with zidovudine/interferon-alpha (AZT-IFN); and 3) AZT-IFN alone, as previously done with Miami cohort (Malpica and Ramos et al. Blood Advances 2018). Treatment response was assessed according to Tsukasaki et al. (JCO 2009) criteria. To be classified as complete response (CR), partial response and stable disease, these had to persist for a period of at least 4 weeks. Survival curves were estimated using the Kaplan-Meier method and Log rank test. RESULTS: A total of 253 pts with ATLL were identified. Two hundred twenty six pts (L=122, A=73, C=26, S=5) had sufficient data for analysis. Demographic and clinical features are shown in Figure 1 and Table 1. Median age at diagnosis was 57 years, with a female predominance in A (58%) and S (100%) types. Most ATLL pts were from Peru (n=159, 63%) followed by Chile (n=44, 17%), Argentina (n=20, 8%) and Colombia (n=17, 7%). B symptoms were high present in A, L and C types (73%, 72%, 58% vs. 8% S type, respectively, p=0.011). Hypercalcemia was highly associated with A type (57% vs. L 27%, p=0.014). The PIT score yielded to a more aggressive risk classification compared to the IPI score (high-risk: 55% vs. 29%, respectively, p CONCLUSION: ATLL continues to carry a dismal outcome with conventional therapies thus urging the development of novel approaches. Our study found that Latin American ATLL variant presents at a younger age, has a female predominance, high incidence of L type, low incidence of indolent types and lower survival rates, suggesting that Latin American ATLL variant presents earlier and more aggressively than in Japanese pts. AZT-IFN produced durable responses in A type patients who achieved CR as compared to chemotherapy alone. Chemotherapy responses were more durable in L types who achieved CR as compared to A type. In conclusion, in the management of aggressive ATLL, chemotherapy remains the preferred choice for L type (with consideration of allo-HSCT upfront), while AZT-IFN is a good option to attempt for A type upfront. Figure Disclosures Peña: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau; BindingSite: Research Funding. Idrobo:Amgen: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Tecnofarma: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau. Altamirano:Hospital Nacional Guillermo Almenara Irigoyen: Other: Servicio de Hematologia. Perini:Abbvie: Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Takeda: Honoraria. Castillo:Janssen: Consultancy, Research Funding; Abbvie: Research Funding; TG Therapeutics: Research Funding; Kymera: Consultancy; Pharmacyclics: Consultancy, Research Funding; Beigene: Consultancy, Research Funding. Ramos:NIH: Research Funding. Villela:Roche: Other: advisory board, Speakers Bureau; amgen: Speakers Bureau.

Published
2020
Full Text
View/download PDF

26. Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)

Author

Ursula Aviles-Perez, Gustavo Sandival-Ampuero, Jorge J. Castillo, Luis Malpica Castillo, Cristaldo Nancy, Mirna Churin, Kelly Meza, Pablo Soto, Luis Villela, Antonio Paredes, Henry Idrobo, Fabiola Valvert, Juan L. Maradei, Luciana Guanchiale, Eloisa Riva, Laura Aguirre-Martinez, Celia Moises, Eduardo M. Sotomayor, Maria Elena Cabrera, Myrna Candelaria, Camila Peña, Bryan Valcarcel, Maria Virginia Prates, Victoria Otero, Juan Antonio Choque, Marcos Di Stefano, Lorena Fiad, Roberto Oviedo-Pecho, Juan Carlos Ramos, Marialejandra Torres Viera, Milagros Altamirano, Gadwyn Sánchez, Andrea Noboa, Guilherme Fleury Perini, Jose Luis Viñuela, Sally Rose Paredes, Denisse Castro, Brady E Beltran, Alana Von Glasenapp, and Daniel J Enriquez

Subjects
medicine.medical_specialty, business.industry, Immunology, Lymphoproliferative disorders, Erythroderma, Alpha interferon, Cell Biology, Hematology, medicine.disease, Biochemistry, Dermatology, Adult T-cell leukemia/lymphoma, Lymphoma, Log-rank test, Leukemia, B symptoms, medicine, medicine.symptom, business
Abstract

INTRODUCTION: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell neoplasm caused by the Human T-cell Leukemia Virus Type 1 (HTLV-1). HTLV-1 infects up to 10 million people worldwide and is most endemic in Southwestern Japan, Western Africa, the Caribbean basin and South America. Cutaneous signs of ATLL are varied and may consist of macules (M), plaques (P), multiple papules (MP), tumoral nodules (TN), erythroderma (E) or mixed-lesions (≥2 predominant lesions, ML). M and P forms are believed to carry a better prognosis. However, data on cutaneous presentation of ATLL remains scarce. Herein, we report cases of ATLL with cutaneous involvement diagnosed in 4 Latin American countries over the last 3 decades. METHODS: We retrospectively analyzed patients (pts) diagnosed with ATLL between January 1995 and December 2019. ATLL subtypes were classified according to the Shimoyama criteria into acute, lymphomatous, chronic and smoldering. Primary cutaneous tumoral (PCT) variant was classified according to the 2019 International Revised ATLL Consensus. We designed 2 cohorts: the first, ATLL pts with cutaneous involvement, and the second, matched cases without cutaneous involvement. We determined the type of skin lesion as well as the survival associated with the various types of skin lesions. We compared the frequency of clinical features using Fisher's exact test. Treatment response was assessed according to Tsukasaki et al. (JCO 2009) criteria. To be classified as complete response (CR), partial response, and stable disease, these had to persist for a period of at least 4 weeks. We analyzed survival data according to ATLL subtype, cutaneous involvement status, and type of skin lesion using the Kaplan-Meier method and Log rank test. RESULTS: A total of 169 pts with ATLL were identified; 63 had cutaneous involvement and 106 did not. Clinical features are shown in Table 1. In both groups the median age was 57 years with a female predominance. Cutaneous involvement was most frequently found in acute (41%) and lymphomatous (37%) ATLL pts. The E (24%) and P (22 %) types were the most frequent skin lesions. Disease stage, presence of B symptoms, hypercalcemia, ECOG ≥2, elevated LDH, and IPI/ PIT score were not different among groups. Table 2 and Table 3 summarize the first-line therapy used and response rates. The use of first-line zidovudine plus interferon alpha (AZT-IFN), regardless of the type of skin lesion, resulted in relatively high response rates [overall response (OR) 100%, n=8; CR 62.5%] as compared to multi agent-chemotherapy (OR 33.3%, n=12). Overall, the presence of cutaneous involvement was associated with better overall survival (OS) compared to non-cutaneous involvement (aHR 0.55 [95% CI: 0.37-0.82], p CONCLUSION: In Latin American pts with aggressive ATLL, cutaneous involvement appears to be associated with better survival compared to non-cutaneous involvement. PCT subtype, an ATLL variant characterized by isolated skin lesions with no organ involvement and poor outcome, appeared to have a better prognosis compared to acute and lymphomatous ATLL forms. P and MP skin lesions were both associated with better survival. Hypercalcemia was found as an independent prognostic factor for survival in pts with cutaneous involvement. Finally, AZT-IFN appears to be reasonable first-line option for aggressive ATLL subtypes with cutaneous involvement regardless of the type of skin lesion at diagnosis, based on the relatively high response rates observed in this subset; further investigation in randomized clinical trials is needed. Disclosures Peña: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau; BindingSite: Research Funding. Idrobo:Takeda: Honoraria, Speakers Bureau; Tecnofarma: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau. Altamirano:Hospital Nacional Guillermo Almenara Irigoyen: Other: Servicio de Hematologia. Perini:Abbvie: Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Takeda: Honoraria. Castillo:Pharmacyclics: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Abbvie: Research Funding; Kymera: Consultancy; TG Therapeutics: Research Funding; Janssen: Consultancy, Research Funding. Ramos:NIH: Research Funding. Villela:amgen: Speakers Bureau; Roche: Other: advisory board, Speakers Bureau.

Published
2020
Full Text
View/download PDF

27. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Author

Wang, Michael, primary, Jain, Preetesh, additional, Lee, Hun Ju, additional, Ok, Chi Young, additional, Hill, Holly, additional, Navsaria, Lucy, additional, Kanagal-Shamanna, Rashmi, additional, Malpica-Castillo, Luis, additional, Nair, Ranjit, additional, Iyer, Swaminathan Padmanabhan, additional, Samaniego, Felipe, additional, Chen, Wendy, additional, Oriabure, Onyeka, additional, Feng, Lei, additional, Thirumurthi, Selvi, additional, Santos, David, additional, Tang, Guilin, additional, Vega, Francisco, additional, Li, Shaoying, additional, Avellaneda, Michelle, additional, Badillo, Maria, additional, and Flowers, Christopher R., additional

Published
2021
Full Text
View/download PDF

29. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma

Author

Malpica-Castillo, Luis, primary, Feng, Lei, additional, Xu, Jie, additional, Nair, Ranjit, additional, Elias, Alexandra, additional, Jain, Preetesh, additional, Chihara, Dai, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Samaniego, Felipe, additional, Ahmed, Sairah, additional, Fowler, Nathan H., additional, Nastoupil, Loretta, additional, Srour, Samer A., additional, Nieto, Yago, additional, Hosing, Chitra, additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Pinnix, Chelsea C., additional, Gunther, Jillian R., additional, Fang, Penny, additional, Wu, Susan, additional, Dabaja, Bouthaina S., additional, Medeiros, Jeffrey, additional, Wang, Michael, additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2021
Full Text
View/download PDF

30. Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Villela, Luis, primary, Beltrán, Brady E., additional, Castro, Denisse, additional, Ramirez-Ibarguen, Ana Florencia, additional, Torres Viera, Marialejandra Alejandra, additional, Perini, Guilherme Fleury, additional, Lome, Carmen, additional, Candelaria, Myrna, additional, Idrobo, Henry, additional, Paredes, Sally Rose, additional, Von Glasenapp, Alana, additional, Valvert, Fabiola, additional, Otero, Victoria, additional, Peña, Camila, additional, Fiad, Lorena, additional, Best, Carlos, additional, Rios, Rosa Oliday, additional, Martinez-Cordero, Humberto, additional, Otañez, Melani, additional, Pérez-Jacobo, Fernando, additional, Ospina Idarraga, Juan, additional, Baena, Rosio, additional, Nancy, Cristaldo, additional, Oliver, Ana Carolina, additional, Irigoín, María Victoria, additional, Cardoso, Larissa Lane, additional, Rodriguez, Yusaima, additional, Macias, Jose, additional, Prates, Maria Virginia, additional, Luna, Maria Alejandra, additional, Cabrera, Maria Elena, additional, Roa, Macarena, additional, Gajardo, Claudia, additional, Díaz, Catalina, additional, Montano Figueroa, Efreen H, additional, Bichara, Erick, additional, Bonfil, Karen Lilian, additional, Cordero-Moreno, Vera Larissa, additional, Valcarcel, Bryan, additional, Castillo, Jorge J., additional, and Malpica Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

31. Clinicopathological Features and Outcomes of EBV Positive and Negative DLBCL: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Castro, Denisse, primary, Beltran, Brady E, additional, Villela, Luis, additional, Montaño Figueroa, Efreen, additional, Ramirez-Ibarguen, Ana Florencia, additional, Candelaria, Myrna, additional, Perini, Guilherme Fleury, additional, Oliver, Ana Carolina, additional, Martinez-Cordero, Humberto, additional, Idrobo, Henry, additional, Rios, Rosa Oliday, additional, Valvert, Fabiola, additional, Paredes, Sally Rose, additional, Pellegrino, Carolina Cristina, additional, Rodriguez, Yusaima, additional, Lopez, Francisco, additional, Irigoin, Victoria, additional, De Galvez, Maria Gabriela, additional, Castillo, Jorge J., additional, Valcarcel, Bryan, additional, and Malpica Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

32. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series

Author

Nair, Ranjit, primary, Deen, Nafis, additional, Ahmed, Sairah, additional, Miranda, Roberto N., additional, Fowler, Nathan H., additional, Fayad, Luis, additional, Steiner, Raphael E, additional, Hagemeister, Fredrick B., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Malpica-Castillo, Luis, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Gunther, Jillian R., additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta, additional, Green, Michael R, additional, Wang, Michael, additional, Vega, Francisco, additional, Feng, Lei, additional, Iyer, Swaminathan Padmanabhan, additional, and Westin, Jason R., additional

Published
2021
Full Text
View/download PDF

33. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Author

Pinnix, Chelsea C., primary, Dabaja, Bouthaina S., additional, Gunther, Jillian R., additional, Fang, Penny, additional, Wu, Susan, additional, Nastoupil, Loretta, additional, Strati, Paolo, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Steiner, Raphael E, additional, Malpica-Castillo, Luis, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Fayad, Luis, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Rodriguez, Maria Alma, additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Wang, Michael, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Feng, Lei, additional, Chi, Linda, additional, and Esmaeli, Bita, additional

Published
2021
Full Text
View/download PDF

34. A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Beltran, Brady E, primary, Castro, Denisse, additional, Villela, Luis, additional, Montaño Figueroa, Efreen, additional, Ramirez-Ibarguen, Ana Florencia, additional, Candelaria, Myrna, additional, Perini, Guilherme Fleury, additional, Oliver, Ana Carolina, additional, Martinez-Cordero, Humberto, additional, Idrobo, Henry, additional, Rios, Rosa Oliday, additional, Valvert, Fabiola, additional, Paredes, Sally Rose, additional, Pellegrino, Carolina Cristina, additional, Rodriguez, Yusaima, additional, Lopez, Francisco, additional, Irigoin, Victoria, additional, De Galvez, Maria Gabriela, additional, Castillo, Jorge J., additional, Valcarcel, Bryan, additional, and Malpica Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

35. Serum Albumin and Neutrophil-to-Lymphocyte Ratio, Two Independent Factor Predicting Survival in Patients with Follicular Lymphoma: A Multi-Institutional Retrospective Cohort of 741 FL, from the Latin American Lymphoproliferative Study Group (GELL)

Author

Torres Viera, Marialejandra Alejandra, primary, Villela, Luis, additional, Beltran, Brady E, additional, Castro, Denisse, additional, Candelaria, Myrna, additional, Idrobo, Henry, additional, Otero, Victoria, additional, Von Glasenapp, Alana, additional, Valvert, Fabiola, additional, Paredes, Sally Rose, additional, Barrios, Juan, additional, Ramirez-Ibarguen, Ana Florencia, additional, Peña, Camila, additional, Cabrera, Maria Elena, additional, Gajardo, Claudia, additional, Roa, Macarena, additional, Díaz, Catalina, additional, Fiad, Lorena, additional, Best, Carlos, additional, Prates, Maria, additional, Ospina, Juan Alejandro, additional, Silva Idárraga, Laura, additional, Martinez, Humberto, additional, Otañez, Melani, additional, Luna, Maria Alejandra, additional, Lome, Carmen, additional, Pérez-Jacobo, Fernando, additional, Baena, Rosio, additional, Macias, Jose, additional, Cristaldo, Nancy, additional, Perini, Guilherme Fleury, additional, Cardoso, Larissa Lane, additional, Rios, Rosa Oliday, additional, Rodriguez, Yusaima, additional, Valcarcel, Bryan, additional, Castillo, Jorge J., additional, and Malpica Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

36. Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell

Author

Perini, Guilherme Fleury, primary, Villela, Luis, additional, Beltran, Brady E, additional, Castro, Denisse, additional, Otero, Victoria, additional, Kalmus, Mariana, additional, Fiad, Lorena, additional, Peña, Camila, additional, Idrobo, Henry, additional, Candelaria, Myrna, additional, Von Glasenapp, Alana, additional, Perdomo, Ivan, additional, Feres, Carolina, additional, Prates, Maria Virginia, additional, Paredes, Sally Rose, additional, Perez-Jacobo, Fernando, additional, Ramirez-Ibarguen, Ana Florencia, additional, Gajardo, Claudia, additional, Salinas, Macarena Alejandra Roa, additional, Otañez, Melani, additional, Valvert, Fabiola, additional, Arcuri, Leonardo Javier, additional, Montaño Figueroa, Efreen, additional, Di Stefano, Marcos, additional, Baena, Rosio, additional, Choque, Juan Antonio, additional, Abello, Virginia, additional, Valladares, Ximena, additional, Sanchez, Sofia, additional, Nancy, Cristaldo, additional, Zambrano, Daniela, additional, Lasso, Juan Felipe, additional, Noboa, Andrea, additional, Rojas, Christine, additional, Teixeira, Larissa LC, additional, Ospina, Juan Alejandro, additional, Torres Viera, Marialejandra Alejandra, additional, Sotomayor, Eduardo, additional, Martinez, Humberto, additional, Castillo, Jorge J., additional, Skarbnik, Alan, additional, and Malpica Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

37. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

Author

Nair, Ranjit, primary, Feng, Lei, additional, Gunther, Jillian R., additional, Xu, Jie, additional, Malpica-Castillo, Luis, additional, Huen, Auris, additional, Torres Cabala, Carlos, additional, Heberton, Meghan, additional, Fang, Penny, additional, Ahmed, Sairah, additional, Miranda, Roberto N., additional, Fayad, Luis, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Srour, Samer A., additional, Nieto, Yago, additional, Nastoupil, Loretta, additional, Pinnix, Chelsea C., additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Hosing, Chitra, additional, Wang, Michael, additional, Dabaja, Bouthaina S., additional, Vega, Francisco, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2021
Full Text
View/download PDF

38. A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma

Author

Valcarcel, Bryan, primary, Castro, Denisse, additional, Enriquez, Daniel J, additional, Peña, Camila, additional, Idrobo, Henry, additional, Fiad, Lorena, additional, Prates, Maria, additional, Paredes, Sally Rose, additional, Torres Viera, Marialejandra Alejandra, additional, Perini, Guilherme Fleury, additional, Castillo, Jorge J., additional, Villela, Luis, additional, Beltran, Brady E, additional, Ramos, Juan Carlos, additional, and Malpica-Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

39. Clinico-Epidemiological Features of Elderly Patients with Peripheral T-Cell Lymphoma Not Otherwise Specified: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Idrobo, Henry, primary, Castro, Denisse, additional, Fiad, Lorena, additional, Huerta- Collado, Yesenia M., additional, Otero, Victoria, additional, Paredes, Sally Rose, additional, Garcia-Robledo, Juan Esteban, additional, Lasso, Juan Felipe, additional, Martinez-Cordero, Humberto, additional, Osorio-Gomez, Ana Maria, additional, Sanchez-Perea, Julian Andres, additional, Valcarcel, Bryan, additional, Villela, Luis, additional, Torres Viera, Marialejandra Alejandra, additional, Beltran, Brady E, additional, Castillo, Jorge J., additional, and Malpica-Castillo, Luis, additional

Published
2021
Full Text
View/download PDF

40. Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)

Author

Denisse Castro, Jorge J. Castillo, Ivan Perdomo, Efreen Montaño Figueroa, Cristobal Augusto Frutos Ortiz, Humberto Martínez Cordero, Mercedes Royg Arriola, Brady E Beltran, Alana Von Glasenapp, Gladys P. Agreda-Vásquez, Eduardo M. Sotomayor, Marcos Distefano, Guillermo J. Ruiz-Argüelles, Camila Peña, Katerine Garcia, Lidiane Andino, Lorena Fiad, Maria Elvira Enciso, Cristaldo Nancy, Carolina Feres, Maria Virginia Prates, Rosio Baena, Henry Idrobo, Sally Rose Paredes, Virginia Otero, Fabiola Valvert, Daniela Zambrano, Luis Villela Villela, Maria Elena Cabrera, Luis E Malpica Castillo, Alfredo Reinaldo Quiroz, Melani Otañez, Juan Ospina Idarraga, Myrna Candelaria, Juan Antonio Choque, Maria Alejandra Torres Viera, Magali DelosRios, Mariana Kalmus, Fernando Perez-Jacobo, Guilherme Fleury Perini, Ana Florencia Ramirez-Ibarguen, Julian Cordova, David Gómez-Almaguer, María Lorena Cardozo, and Eloisa Riva

Subjects
medicine.medical_specialty, Latin Americans, business.industry, Immunology, Hazard ratio, Retrospective cohort study, Cell Biology, Hematology, medicine.disease, Biochemistry, International Prognostic Index, Family medicine, Honorarium, Cohort, Risk of mortality, Medicine, business, Diffuse large B-cell lymphoma
Abstract

Introduction. There are different scoring systems to differentiate risk groups in patients with DLBCL treated with chemoimmunotherapy. Those systems have used the same 5 variables (age, performance status, LDH, stage, extranodal involvement) for 27 years. However, LATAM data have not been included in the development of previous scoring systems. It is important to mention that novel biological variables, such as albumin, beta-2-microglobulin (B2M) and platelet/lymphocyte ratio (PLR), have been reported and could improve discrimination (Villela et al. Blood 2019; 134Suppl_1: 1613). Therefore, we carried out a large, multinational study to develop and validate a LATAM-IPI score. Methods. This is a retrospective cohort of 1030 patients with a diagnosis of DLBCL treated with standard chemoimmunotherapy with curative intent between 2010 and 2018. Data were obtained from 8 LATAM countries: Argentina, Colombia, Chile, Guatemala, Mexico, Paraguay, Peru, and Venezuela. The five classic IPI variables (age, ECOG, extranodal involvement, LDH, stage) were analyzed and albumin and PLR were added (Villela et al. Blood 2019; 134Suppl_1: 1613). B2M was not included because it was not requested regularly in all countries. Development of LATAM-IPI: The training set consisted of 85% of the sample, randomly selected, and the remaining 15% was reserved for internal validation. Using the training set, the univariate and multivariate association between clinical prognostic factors and OS was analyzed fitting Cox proportional-hazard models. Outcomes. Clinical characteristics of the training (n=878) and internal validation (n=151) cohorts are shown in Table 1. There were no statistical differences in baseline characteristics between the cohorts. The median follow-up for the whole cohort was 36 months (IQR: 11-57). When exploring the classic IPI variables on the training set, all variables were associated with high risk of mortality [age 65-74, Hazard Ratio (HR) 1.24, 95% CI 0.96 to 1.58, p=0.08; age ≥75, HR 1.71, 95% CI 1.28 to 2.28, p=0.0003), ECOG (≥ 2, HR=2, 95% CI 1.61 to 2.53; p Conclusions: Using multinational learning and validation cohorts including over 1,000 DLBCL patients treated with standard chemoimmunotherapy in LATAM, we developed a novel LATAM-IPI score using age ≥75 years, ECOG ≥2, advanced stage, LDH ratio (1.1-29 and ≥3) and albumin Disclosures Villela: amgen: Speakers Bureau; Roche: Other: advisory board, Speakers Bureau. Idrobo:Janssen: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau; Tecnofarma: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau. Gomez-Almaguer:Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Castillo:Janssen: Consultancy, Research Funding; TG Therapeutics: Research Funding; Kymera: Consultancy; Abbvie: Research Funding; Beigene: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding.

Published
2020
Full Text
View/download PDF

41. Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Candelaria, Myrna, Villela Martinez, Luis Mario, Beltran, Brady E, Ramirez, Ana Florencia, Torres Viera, Marialejandra, Oliver, Carolina, Quintero, Henry Idrobo, perez-Jacobo, Fernando, Perini, Guilherme Fleury, Peña, Camila, Korin, Laura, Castro, Denisse, Irigoín, Victoria, Paredes, Sally Rose, Hernandez-Hernandez, Jose A, Colunga-Pedraza, Perla R., Gomez-Almaguer, David, Ruiz-Argüelles, Guillermo, Otañez, Melani, Castillo, Jorge J., and Malpica Castillo, Luis Enrique

Published
2023
Full Text
View/download PDF

42. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Author

Westin, Jason, Steiner, Raphael E, Chihara, Dai, Ahmed, Sairah, Jain, Preetesh, Malpica, Luis, Iyer, Swami P., Fayad, Luis, Nair, Ranjit, Nastoupil, Loretta J., Neelapu, Sattva S., Henderson, Jared, Rodriguez, Maria Alma, Hagemeister, F. B., Vega, Francisco, Pulsifer, Brittani, Tom, Jisha, Durmic, Isak, Masand, Gita, Feng, Lei, Green, Michael R., Flowers, Christopher R., and Strati, Paolo

Published
2023
Full Text
View/download PDF

43. Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America

Author

Fischer, Thais, Idrobo, Henry, Pavlovsky, Astrid, Castro, Denisse, Beltran, Brady, Enriquez, Daniel J, Vasquez, Jule F, Roche, Claudia, Artiles, Daniel, Valvert, Fabiola, Villela, Luis Mario, Pereira, Juliana, Oliver, Carolina, Tavarez, Jamila Vaz, Brasil, Sergio Augusto B, Cecyn, Karin Z, Castro, Nelson, Baptista, Renata, Medina, Samuel de S, Borducchi, Davimar Miranda Maciel, Bellesso, Marcelo, De Farias, Danielle Leao Cordeiro, Gonzaga, Yung Bruno, Warley, Fernando, Fiad, Lorena, Korin, Laura, Pereyra, Patricio Hernan, Peña, Camila, Torres, Maria Alejandra, Mahuad, Carolina Valeria, Von Glasenapp, Alana, Quiroz, Alfredo Reinaldo, Gazitua, Raimundo, Samanez-Figari, Cesar Augusto, Sardu, Lautaro, Arriola, Juan Pablo, Isnardi, Sebastian, Maradei, Juan L., Gabus, Raul Hector, Enrico, Alicia I., Guanchiale, Luciana A, Arangueren, Florencia Negri, Altuve, Juan Ignacio García, Cerutti, Amalia, Penalva, Romina, Trucco, Jose Ignacio Garcia, Pessolani, Florencia, Gilli, Virginia, Diaz, Joaquin, Martinez, Maria Enriqueta, Jarchum, Gustavo, Perinotto, Gabriela Celia, Barraza, Teresa, Ciarlo, Sergio, Rojas, Christine, Rios Jiménez, Rosa Oliday, De Souza, Carmino, Manni, Martina, Miranda, Eliana C M CM, Federico, Massimo, Valcarcel, Bryan, Chiattone, Carlos, and Malpica Castillo, Luis Enrique

Published
2023
Full Text
View/download PDF

44. Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

Author

Ruan, Jia, Chen, Zhengming, Larson, Melissa C., Bennani, N. Nora, Wallace, Danielle, Allen, Pamela B., Jaye, David L, Cohen, Jonathon B., Malpica Castillo, Luis Enrique, Vega, Francisco, Inghirami, Giorgio, Mou, Eric, Casulo, Carla, Mehta-Shah, Neha, Martin, Peter, Maurer, Matthew J., Kahl, Brad S., Lossos, Izidore S., Cerhan, James R., Flowers, Christopher R., and Feldman, Andrew L.

Published
2023
Full Text
View/download PDF

45. Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Author

Jain, Preetesh, Young OK, Chi, Nastoupil, Loretta J., Westin, Jason, Hill, Holly A, Nair, Ranjit, Iyer, Swami P., Fetooh, Ahmed, Lee, Hun Ju, Ahmed, Sairah, Kanagal-Shamanna, Rashmi, Jelloul, Fatima Z, Malpica Castillo, Luis Enrique, Liu, Yang, Li, Yijing, Vargas, Jovanny, Feng, Lei, Badillo, Maria, Thirumurthi, Selvi, Xu, Guofan, Deswal, Anita, Iliescu, Cezar, Quang Nguyen, Vinh, Tang, Guilin, Patel, Keyur P., Vega, Francisco, Medeiros, L. Jeffrey, Wang, Michael L., and Flowers, Christopher R.

Published
2023
Full Text
View/download PDF

47. Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Author

Perini, Guilherme Fleury, Idrobo, Henry, Oliver, Carolina, Von Glasenapp, Seisha Alana, Castro, Denisse, Villela Martinez, Luis Mario, Beltran, Brady, Stemmelin, German R., Candelaria, Myrna, Colunga-Pedraza, Perla R., Diaz, Joaquin, Korin, Laura, Ospina Idarraga, Juan, Martinez-Cordero, Humberto, Chiattone, Carlos, Dias, Maria Almeida, Baena, Rosio, Paredes, Sally Rose, Torres Viera, Marialejandra, Rios Jiménez, Rosa Oliday, Valvert, Fabiola, Warley, Fernando, Rivarola, Sofía Gabriela, Guanchiale, Luciana A, Ranero Ferrari, Sabrina, Pereyra, Patricio Hernan, Bogado Colmán, Juan José, Hernandez, Marcos, Abello, Virginia, Robles Rodriguez, Arianna, Roa, Macarena, Salinas, Virgilio ALBERTO, Macias Abasto, Jose Marcial, Spinelli, Virginia Lema, Bellesso, Marcelo, Malpica Castillo, Luis Enrique, and Castillo, Jorge J.

Published
2023
Full Text
View/download PDF

48. Validating the Systemic Inmmune-Inflamation Index (SII) As a Prognostic Biomarker of Overall Survival in Diffuse Large B-Cell Lymphoma: A Retrospective Analyses By the Gruppo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Author

Villela Martinez, Luis Mario, Beltran, Brady E, Candelaria, Myrna, Ramirez, Ana Florencia, Torres Viera, Marialejandra, Oliver, Carolina, Quintero, Henry Idrobo, perez-Jacobo, Fernando, Robles Rodriguez, Arianna, Perini, Guilherme F, Peña, Camila, Korin, Laura, Castro, Denisse, Irigoín, Victoria, Paredes, Sally Rose, Hernandez-Hernandez, Jose A, Colunga-Pedraza, Perla R., Gomez-Almaguer, David, Ruiz-Argüelles, Guillermo, Otañez, Melani, Rios Jiménez, Rosa Oliday, Gil Rondero, Carlos, Castillo, Jorge J., Valvert, Fabiola, and Malpica, Luis

Published
2023
Full Text
View/download PDF

49. Validating the Halp Score (Hemoglobin,Albumin, Lymphocytes, and Platelets) and the Neutrophil/Lymphocyte Ratio ( NLR) As Prognostic Factors for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Retrospective Analysis By the Grupo De Estudio De Latino America De Linfoproliferativos (GELL)

Author

Villela Martinez, Luis Mario, Beltran, Brady E, Candelaria, Myrna, Torres Viera, Marialejandra, Ramirez, Ana Florencia, Quintero, Henry Idrobo, Oliver, Carolina, Perini, Guilherme Fleury, Montano Figueroa, Efreen H, Korin, Laura, Fiad, Lorena, Stemmelin, German R., Perez-Jacobo, Fernando, Castro, Denisse, Paredes, Sally Rose, Irigoín, Victoria, Colunga-Pedraza, Perla R., Gomez-Almaguer, David, Ruiz-Argüelles, Guillermo, Valvert, Fabiola, Otañez, Melani, Robles Rodriguez, Arianna, Best, Carlos, Hernandez-Hernandez, Jose A, Malpica, Luis, and Castillo, Jorge J.

Published
2023
Full Text
View/download PDF

50. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Author

Westin, Jason, Nair, Ranjit, Fayad, Luis, Iyer, Swami P., Malpica, Luis, Neelapu, Sattva S., Samaniego, Felipe, Steiner, Raphael Eric, Strati, Paolo, Mathew, Shivon, Griffith, Donna, Nastoupil, Loretta J., Montinez, Wirt, Rodriguez, Maria Alma, Hagemeister, Frederick, Feng, Lei, Vega, Francisco, Flowers, Christopher R., and Ahmed, Sairah

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results